Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 156

Sort by

Sort Order Select

Journal Articles

Cytopenias and Failure to Use Innovative Therapy Are Main Drivers of Worse Outcome after Discontinuation of Ruxolitinib in Myelofibrosis

Blood (2024) 144 (Supplement 1): 6664.

https://doi.org/10.1182/blood-2024-199961

Published: 2024

Journal Articles

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Pankit Vachhani, Raajit Rampal, Terrence Bradley, Claire Harrison, Tania Jain, Andrew T. Kuykendall, Francesca Palandri, John O. Mascarenhas, Haifa Kathrin Al-Ali, Francesco Passamonti, Anna Nekhymchuk, Hilarie Foss, Wayne Rothbaum, Srdan Verstovsek, Florian Heidel

Blood (2024) 144 (Supplement 1): 1808.2.

https://doi.org/10.1182/blood-2024-200966

Published: 2024

Journal Articles

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Nico Gagelmann, Barbara Mora, Filippo Branzanti, Alessandro Maria Vannucchi, Massimo Breccia, Giuseppe Alberto Maria Palumbo, Massimiliano Bonifacio, Erika Morsia, Elena Maria Elli, Mario Tiribelli, Giulia Benevolo, Mirko Farina, Fabrizio Pane, Roberto Massimo Lemoli, Giovanni Caocci, Alessia Tieghi, Gianni Binotto, Francesco Cavazzini, Bruno Martino, Alessandro Isidori, Margherita Maffioli, Elisa Rumi, Tiziano Barbui, Francisco Cervantes, Matteo Giovanni Della Porta, Andrew T. Kuykendall, Marianna Caramella, Alessandra Iurlo, Valerio De Stefano, Jean-Jacques Kiladjian, David Ross, Jason Gotlib, Timothy Devos, Marco Ruggeri, Richard T. Silver, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Christina Rautenberg, Marie Robin, Marie-Thérèse Rubio, Jaroslaw Maciejewski, Alessandro Rambaldi, Maria Chiara Finazzi, Andrea Bacigalupo, Patrizia Chiusolo, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger, Francesco Passamonti, Francesca Palandri

Blood (2024) 144 (Supplement 1): 245.

https://doi.org/10.1182/blood-2024-210804

Published: 2024

Journal Articles

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Blood (2024) 144 (Supplement 1): 658.

https://doi.org/10.1182/blood-2024-200925

Published: 2024

Journal Articles

Reliable Assessment of Iron Deficiency in Patients with Myeloproliferative Neoplasms through Fluorescence Spectroscopy-Based Measurement of Zinc Protoporphyrin (ZPP)

Kirsi Manz, Myriam Kobrosly, Carl C Crodel, Haifa Kathrin Al-Ali, Susanne Isfort, Gernot Beutel, Victoria Panagiota, Felicitas R. Thol, Stefanie Jilg, Thomas Stauch, Wolfgang Hoffmann, Henry Völzke, William H Krüger, Andreas Hochhaus, Francesca Palandri, Tina M Schnoeder, Christian Homann, Florian H. Heidel

Blood (2024) 144 (Supplement 1): 1090.

https://doi.org/10.1182/blood-2024-205036

Published: 2024

Journal Articles

Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 3178.

https://doi.org/10.1182/blood-2024-193193

Published: 2024

Journal Articles

Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison

Francesca Palandri, Venediktos Kapetanakis, Balazs Dobi, Filippo Branzanti, Catherine Ellis, Nick Ballew, Tom Liu, Kelesitse Phiri, Fulya Sen Nikitas, Melania Biasi, Shiyuan Zhang, Dwaipayan Patnaik

Blood (2024) 144 (Supplement 1): 3187.

https://doi.org/10.1182/blood-2024-205973

Published: 2024

Journal Articles

Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial

Blood (2024) 144 (Supplement 1): 997.

https://doi.org/10.1182/blood-2024-201729

Published: 2024

Journal Articles

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Blood (2024) 144 (Supplement 1): 6635.

https://doi.org/10.1182/blood-2024-199028

Published: 2024

Journal Articles

Improvement in Serum Albumin As a Measure of Improved Metabolic Profile in Pacritinib-Treated Patients: A Retrospective Analysis of Patients Treated across Three Clinical Trials

Francesca Palandri, Marta Sobas, Claire Harrison, Raajit Rampal, Sarah Buckley, Purvi Suthar, Karisse Roman-Torres, John O. Mascarenhas

Blood (2024) 144 (Supplement 1): 3191.

https://doi.org/10.1182/blood-2024-192908

Published: 2024

Journal Articles

Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study

Blood (2024) 144 (Supplement 1): 242.

https://doi.org/10.1182/blood-2024-200528

Published: 2024

Journal Articles

Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States

Andrew T. Kuykendall, Francesca Palandri, Shiyuan Zhang, Tom Liu, Mirko Fillbrunn, Adina Zhang, Gautam Sajeev, James Signorovitch, Dwaipayan Patnaik, Aaron T. Gerds

Blood (2024) 144 (Supplement 1): 3804.

https://doi.org/10.1182/blood-2024-205380

Published: 2024

Journal Articles

Clinical Implications of Plasma-Derived Extracellular Vesicles in Myeloproliferative Neoplasms: Unveiling Inflammatory Potential and Biomarkers for Cancer Treatment

Ghazal Narimanfar, Dorian Forte, Roberto Maria Pellegrino, Francesca Perut, Filippo Maltoni, Martina Barone, Alessia Brancolini, Filippo Branzanti, Virginia Pucci, Elisabetta Lugli, Alessia Tieghi, Carla Emiliani, Regina Grillari, Pier Luigi Zinzani, Francesca Palandri, Lucia Catani

Blood (2024) 144 (Supplement 1): 1754.

https://doi.org/10.1182/blood-2024-210011

Published: 2024

Journal Articles

Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients

Daniele Cattaneo, Barbara Mora, Cristina Bucelli, Margherita Maffioli, Elena Maria Elli, Giulia Benevolo, Valentina Bellani, Emilia Scalzulli, Filippo Branzanti, Paola Bianchi, Marta Lionetti, Bruno Martino, Umberto Gianelli, Niccolò Bolli, Francesca Palandri, Massimo Breccia, Dario Consonni, Alessandra Iurlo

Blood (2024) 144 (Supplement 1): 4550.

https://doi.org/10.1182/blood-2024-211145

Published: 2024

Journal Articles

ELN Criteria for Cytoreduction Start Identify Patients with Polycythemia Vera at Higher Thrombotic Risk

Blood (2023) 142 (Supplement 1): 4527.

https://doi.org/10.1182/blood-2023-181553

Published: 2023

Journal Articles

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study

Claire N Harrison, Ruben Mesa, Moshe Talpaz, Haifa Kathrin Al-Ali, Blanca Xicoy, Francesco Passamonti, Francesca Palandri, Giulia Benevolo, Alessandro M. Vannucchi, Clemence Mediavilla, Alessandra Iurlo, InHo Kim, Patrick Brown, Christopher Hernandez, Shelonitda Rose, Jia Wang, Jean-Jacques Kiladjian

Blood (2023) 142 (Supplement 1): 3204.

https://doi.org/10.1182/blood-2023-173391

Published: 2023

Journal Articles

Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations

Blood (2023) 142 (Supplement 1): 747.

https://doi.org/10.1182/blood-2023-179329

Published: 2023

Journal Articles

Bromodomain and Extra-Terminal Inhibitor INCB057643 (LIMBER-103) in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Justin M. Watts, Alessandro M. Vannucchi, Anthony M. Hunter, Brandon McMahon, Srinivas K. Tantravahi, Alessandra Iurlo, Blanca Xicoy, Francesca Palandri, Emma Searle, Brandi N. Reeves, Prithviraj Bose, Rosa Ayala, Anna B. Halpern, Xuejun Chen, Lea M Burke, Feng Zhou, Fred Zheng, Pankit Vachhani

Blood (2023) 142 (Supplement 1): 750.

https://doi.org/10.1182/blood-2023-179428

Published: 2023

Journal Articles

Ruxolitinib Treatment in Polycythemia Vera Results in Reduction in JAK2 Allele Burden in Addition to Improvement in Hematocrit Control and Symptom Burden

Claire N Harrison, Jean-Jacques Kiladjian, Francesca Palandri, JE Hamer-Maansson, Evan M. Braunstein, Francesco Passamonti

Blood (2023) 142 (Supplement 1): 4553.

https://doi.org/10.1182/blood-2023-179439

Published: 2023

Journal Articles

Impact of Symptom Benefit and Transfusion Response on Survival in Myelofibrosis Patients Treated with Pacritinib: PERSIST-2 Landmark Survival Analysis

Helen Ajufo, Jan Philipp Bewersdorf, Claire N Harrison, Francesca Palandri, John Mascarenhas, Jeanne Palmer, Aaron T. Gerds, Jean-Jacques Kiladjian, Sarah Buckley, Andriy Derkach, Karisse Roman-Torres, Raajit K. Rampal

Blood (2023) 142 (Supplement 1): 3207.

https://doi.org/10.1182/blood-2023-177643

Published: 2023

NARROW

Cytopenias and Failure to Use Innovative Therapy Are Main Drivers of Worse Outcome after Discontinuation of Ruxolitinib in Myelofibrosis

POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitor INCB057643 in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Reliable Assessment of Iron Deficiency in Patients with Myeloproliferative Neoplasms through Fluorescence Spectroscopy-Based Measurement of Zinc Protoporphyrin (ZPP)

Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with Myelofibrosis

Overall Survival with Momelotinib Vs Best Available Therapy in Patients with Ruxolitinib-Experienced Myelofibrosis: A Matching-Adjusted Indirect Comparison

Hematological Improvement and Other Clinical Benefits of Elritercept As Monotherapy and in Combination with Ruxolitinib in Participants with Myelofibrosis from the Ongoing Phase 2 Restore Trial

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Improvement in Serum Albumin As a Measure of Improved Metabolic Profile in Pacritinib-Treated Patients: A Retrospective Analysis of Patients Treated across Three Clinical Trials

Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study

Retrospective Real-World Analysis of Survival Outcomes in Patients with Myelofibrosis and New or Worsening Anemia Treated with Ruxolitinib in the United States

Clinical Implications of Plasma-Derived Extracellular Vesicles in Myeloproliferative Neoplasms: Unveiling Inflammatory Potential and Biomarkers for Cancer Treatment

Prognostic Insights on PRE-Fibrotic Primary Myelofibrosis: A Clinical-Pathological Perspective in 762 Patients

ELN Criteria for Cytoreduction Start Identify Patients with Polycythemia Vera at Higher Thrombotic Risk

Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study

Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations

Bromodomain and Extra-Terminal Inhibitor INCB057643 (LIMBER-103) in Patients with Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study

Ruxolitinib Treatment in Polycythemia Vera Results in Reduction in JAK2 Allele Burden in Addition to Improvement in Hematocrit Control and Symptom Burden

Impact of Symptom Benefit and Transfusion Response on Survival in Myelofibrosis Patients Treated with Pacritinib: PERSIST-2 Landmark Survival Analysis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only